Latest News
Clinical trial results released Nov. 29 for lecanemab, a drug targeting early Alzheimer’s disease, reported a moderate slowing of cognitive decline in patients by 25% through the removal of amyloid-beta (Aβ) in the brain.
If approved, the drug pegcetacoplan would become the first-ever treatment in the U.S. for geographic atrophy, a blinding and advanced form of age-related macular degeneration.
More than 75 graduate students, postdoctoral fellows, and other early-career scientists from around the world participated in this year’s BrightFocus Alzheimer’s Fast Track, Nov. 9-11, 2022, in San Diego.
Gael Chetelat, PhD, University of Caen-Normandy, France, was honored on Oct. 21, 2022, by Women’s Health Access Matters for her BrightFocus-funded project, “Sex Differences in Risk Profiles Across the Alzheimer’s Disease Continuum.”
In this issue:
- President’s Corner
- One-Time Gene Therapy for Wet AMD
- DNA Modifcation and Gene Expression in AMD
- And more!
In this issue:
- President’s Corner
- Researcher Spotlight: Shannon Macauley, PhD
- Rare APOE Variant Reduces Plaques Linked to Alzheimer’s
- And more!
In this issue:
- Glaucoma and Corneal Thickness
- President’s Corner
- Identifying New Risk Factors and Treatments for Glaucoma
- And more!
BrightFocus Foundation’s 2022 annual report highlights an incredible year of pioneering neurodegenerative research.
A recent article coauthored by BrightFocus Vice President, Scientific Affairs Diane Bovenkamp, PhD, proposes a new way to narrow racial and ethnic disparities in Alzheimer’s research through the development of standardized electronic health records.
BrightFocus Foundation yesterday presented its first-ever Alzheimer’s Disease Research (ADR) named awards to two leading researchers in recognition of their innovative work to prevent, treat, and, ultimately, cure Alzheimer’s disease.
